The latter make it an attractive target in kidney diseases since specifically targeting EP receptors, such as EP4, might lead to more specific effects compared to drugs, which target the biosynthesis of PGE2 or prostaglandin production in general and thereby have a plethora of side effects including renal toxicity [1,3]. Here, PTGER4 is linked to kidney disorder.